MENU
DEC 03, 2020 7:30 AM PST

Keynote Presentation: Prevalence of SARS-CoV-2 Immunity in Those Undiagnosed with COVID-19 in the U.S.

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Biography

      Dr. Memoli is a graduate of the College of William and Mary and he received his master’s degree in microbiology from Thomas Jefferson University in Philadelphia, PA. He then received his medical degree from St George’s University School of Medicine. He completed a residency in internal medicine at the Washington Hospital Center Georgetown University Internal Medicine Program in Washington, DC. After completing an infectious disease fellowship in NIAID at the National Institutes of Health, Dr. Memoli developed a clinical/translational research program to study influenza and other respiratory viruses in the Laboratory of Infectious Diseases. He now serves as the Director of the LID Clinical Studies Unit (CSU) that seeks to perform translational research studies to answer fundamental questions regarding human influenza, respiratory viruses, and other emerging viral infections to inform and impact future vaccine and therapeutic design, while also making an effort to assist in evaluation of novel products that may impact human health. With a focus on healthy volunteer research, the LID CSU has been able to continue their primary work on influenza while quickly able to respond to assist in research of emerging infections.  Dr. Memoli is considered a leading expert in healthy volunteer challenge trials, respiratory virus infections, and influenza vaccines. In addition, in recent years Dr. Memoli’s LID CSU has been heavily involved in the NIH response to emerging threats including the 2009 Influenza Pandemic, Zika, EBOLA, and COVID19.


    Abstract

    The 2020 SARS-CoV-2 pandemic is now the 5th respiratory virus pandemic since 1918.  No matter the time in history that these pandemics occur and no matter the severity we see public health efforts and scientists stymied in their efforts to truly change the course of these pandemics.  The reasons for this are numerous as there are so many unanswered questions regarding respiratory virus infections that lead to many of the failed, confusing, and sometimes harmful actions taken by governments, health officials, and physicians/scientists.  In order to address the current and future pandemics we must work hard to better understand the correlates of protection of respiratory viruses.  During the early stage of this pandemic we started a trial to look at the prevalence of SARS-CoV2 antibody in a nationwide sampling of individuals who were not diagnosed with COVID19.  The goal of this study was to achieve a highly representative sample that could be used to estimate the true prevalence nationwide and in different groups based on multiple demographic and other factors.  This study performed April to August, gave us the opportunity to take an early sample and then currently follow up at 6 and 12 months to assess change over time, longevity of response, and begin to probe questions regarding correlates of protection.  This study sets the stage for much more work and raises questions that will need to be addressed in future studies. With focused efforts and thoughtful science, we can achieve a much better understanding of respiratory viruses and the correlates of protection.  This will require significant collaboration, communication, and of course funding.  It is important that we try to get this right so that we are better prepared for the next pandemic and do not find ourselves still in the same situation we have been in during every pandemic since 1918.

    Learning Objectives:

    1. Define SARS-CoV-2 immunity, antibody testing, and discuss what is known about the meaning of these tests

    2. Identify challenges in doing research during social distancing and demonstrate methods to overcome those challenges

    3. Explain the findings of the NIH serosurvey in terms of prevalence of SARS-CoV-2 immunity by geography and demographic groups


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more